PMDA — authorised 20 September 2019
- Marketing authorisation holder: BioMarin Pharmaceutical Japan K.K.
- Status: approved
🇯🇵 Rhttp1 in Japan
PMDA authorised Rhttp1 on 20 September 2019
Marketing authorisation
Rhttp1 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in Japan
Frequently asked questions
Is Rhttp1 approved in Japan?
Yes. PMDA authorised it on 20 September 2019.
Who is the marketing authorisation holder for Rhttp1 in Japan?
BioMarin Pharmaceutical Japan K.K. holds the Japanese marketing authorisation.